drugset / Trial / NCT06519097
Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)
Phase 2
Active not recruiting
4 enrolled
H. Lee Moffitt Cancer Center and Research Institute
American River Nutrition, LLC · collabNational Cancer Institute (NCI) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled trial, investigating whether treatment with δ-tocotrienol (a.k.a. Delta-tocotrienol, abbreviated as DT3) will prevent the progression of Intraductal Papillary Mucinous Neoplasm (IPMN) of the pancreas.
Timeline
- Start
- 2024-07-09
- Primary completion
- 2026-09
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Delta-tocotrienol | Other / unclassified | 400 mg | Oral |